Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

BACKGROUND: Cytomegalovirus (CMV) infections that are refractory or resistant (RR) to available antivirals ([val]ganciclovir, foscarnet, cidofovir) are associated with higher mortality in transplant patients. Maribavir is active against RR CMV strains. METHODS: Hematopoietic-cell or solid-organ tran...

Descripción completa

Detalles Bibliográficos
Autores principales: Papanicolaou, Genovefa A, Silveira, Fernanda P, Langston, Amelia A, Pereira, Marcus R, Avery, Robin K, Uknis, Marc, Wijatyk, Anna, Wu, Jingyang, Boeckh, Michael, Marty, Francisco M, Villano, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451997/
https://www.ncbi.nlm.nih.gov/pubmed/30329038
http://dx.doi.org/10.1093/cid/ciy706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451997/
https://www.ncbi.nlm.nih.gov/pubmed/30329038
http://dx.doi.org/10.1093/cid/ciy706

Ejemplares similares